Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo Carnerero E, Merino O, Nantes Castillejo Ó, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Pineda JR, Sampedro MJ, Serra Nilsson K, Bouhmidi A, Batista L, Muñoz Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín Jiménez I, Torrella E, Vera Mendoza M, Casanova MJ, de Francisco R, Arias-González L, Marín Pedrosa S, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Núñez-Ortiz A, Vicuña Arregui M, Bosca-Watts MM, Blázquez I, Acosta D, Garre A, Baldán M, Martínez C, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Chaparro M; EXIT Study group of GETECCU. Gisbert JP, et al. Among authors: rivero m. Gut. 2024 Dec 20:gutjnl-2024-333385. doi: 10.1136/gutjnl-2024-333385. Online ahead of print. Gut. 2024. PMID: 39794921 Free article.
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence.
Giordano A, Pérez-Martínez I, Gisbert JP, Ricart E, Martín-Arranz MD, Mesonero F, De Castro Parga ML, Rivero M, Iglesias E, Fernández-Prada S, Calafat M, Arroyo Villarino MT, Ángel de Jorge Turrión M, Hernandez-Camba A, Lidón RV, Carpio D, Brunet E, Moranta FR, García LA, Cuquerella JT, Bermejo F, Madero L, Esteve M, González-Muñoza C, Martínez-Montiel P, Huguet JM, Pérez Calle JL, Rodríguez-Lago I, Ausín MS, Lorente Poyatos RH, García-Bosch O, Marín GS, Taxonera C, Ponferrada-Diaz Á, Acosta MB, Bujanda L, Serra RB, Ramos L, Vera I, Abizanda ES, Piqueras M, Gómez CS, García-Sepulcre MF, Arregui MV, Murillo NR, LLaó J, Lucendo AJ, Marín-Jiménez I, Camps-Aler B, Villafranca CM, Ceballos D, Ver Y, Fernández-Salazar LI, Alcaín G, Valldosera G, Andrés PR, Martínez-Flores C, Coronel AF, Ginard D, García L, Gómez IB, Argüelles-Arias F, Miyashiro EI, De la Piscina PR, Villalba LH, Notari PA, de Jesús Martínez-Pérez T, Fernández H, Gilabert P, Rosas CM, Nos P, Gil JL, Navas López VM, Muñoz F, Diz-Lois Palomares MT, Lucio AS, Merino O, Nicolás de Prado I, Leal C, Martín de Carpi J, Sánchez LB, Arce NM, Frago S, Mateu BB, Domènech E, Planella EG; ENEIDA project of GETECCU. Giordano A, et al. Among authors: rivero m. Am J Gastroenterol. 2025 Jan 1;120(1):194-203. doi: 10.14309/ajg.0000000000003207. Epub 2024 Nov 14. Am J Gastroenterol. 2025. PMID: 39745305
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2024 Dec 23:dkae456. doi: 10.1093/jac/dkae456. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39710424
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209 Clinical Trial.
596 results